TAKE Solutions to launch
TAKE Solutions to launch 'track and trace'
supply chain management tool
TAKE Solutions Pte Ltd, a technology enabled business
solutions company with leadership in supply chain management and life sciences,
will soon be launching 'track and trace', a supply chain management tool.
Speaking to BioSpectrum, S Sridharan, managing
director, Take Solution Pte Ltd said, "The companies in life sciences and
pharmaceuticals have to adopt Radio Frequency Identification (RFID), an
automatic identification method to cut the distribution cost. Even the FDA
guidelines say its mandatory for them to adopt RFID by 2008. A few Indian
companies have already adopted this. We see a good market potential for this in
the near future."
TAKE Solutions recently launched Submit SPL software that
helps life sciences companies to easily manage XML data conversion to be
compliant with the Structured Product Labeling (SPL) standard of the US FDA.
Sharing his views on Submit SPL, Sridharan said, "About 300 labels were
submitted to the FDA for approval in the last three months. These labels were
produced using our product."
TAKE has over ten products addressing the SCM and manufacturing space. TAKE
Solutions that has operations in the USA, Sri Lanka, Malaysia and Bahrain with
an employee strength of 370, posted revenue of Rs 44.07 crore for the year ended
March 31, 2005 as against Rs 14.91 crore for the previous year.
Sartorius secures key technology for disposable
bioreactors
Sartorius AG and the US-based Fluorometrix Corp, a spin-off
of the University of Maryland, have concluded a licensing contract that gives
Sartorius exclusive use of Fluorometrix patents in the field of disposable
sensors for bioreactors. The addition of disposable sensors for detection of
multiple parameters completes the Sartorius portfolio of technology for the
development and construction of disposable bioreactors. Sartorius has plans for
implementing these sensors as platform technology in other new products as well.
"We have secured a strategic advantage for Sartorius in the rapidly growing
market for disposables. The current technological challenge for the creation of
disposable bioreactors lies in the use of disposable products for all components
of the system – including measurement and control units. The new disposable
sensors complete the chain and ensure that in this year we will be one of the
first companies to introduce a completely disposable reactor," said
Reinhard Vogt, senior vice president of sales and marketing for the Sartorius
biotechnology division.
The bioreactor is at the core of every biotechnological production process:
this is where microorganisms are bred under controlled conditions and either
their cells or the products of their metabolic processes are harvested for use
in the manufacture of pharmaceutical agents. Up to now, virtually all reactors
on the market were reusable systems. Sartorius has been working on the
development of bioreactors as disposable systems to meet the stringent
requirements of the pharmaceutical industry regarding safety and hygiene.
Waters enhances BA software for quantitative and
qualitative research
Waters Corporation has announced a new version of its
ProteinLynx Global SERVER software, including enhancements to Waters Protein
Expression System. Waters ProteinLynx Global SERVER (PLGS) 2.2.5 software
features new tools allowing researchers to identify and quantify proteins and
biomarkers more efficiently.
Waters Protein Expression System, featuring PLGS, was the
first commercial product for cost-effective and practical quantitative
proteomics without the use of isotope labeling technologies. PLGS 2.2.5 extends
this breakthrough technology with improved algorithms for efficient protein
quantification and identification across large patient/sample sets or
time-course studies.
A new quantification module in PLGS allows quantitative data
to be generated at the protein or peptide level using any of the commercially
available or user-defined labeling technologies such as SILAC, AQUA, ICAT or
iTRAQ. The ability to perform both 'label free' and 'isotopic labeling'
approaches now means that PLGS provides unparalleled flexibility to analyze
proteomics samples of varying type and complexity.
PLGS 2.2.5 provides a 'step change' in the ability to identify proteins
efficiently in complex samples by incorporating a new algorithm, which enables
identification of proteins from MS E data (E - elevated collision energy)
acquired from a Q-Tof type mass spectrometer. In an LC/MS experiment, a
proprietary and patented 'parallel' peptide fragmentation protocol is
employed to provide a 100 percent duty cycle on all detectable peptides in a
protein digest. This new approach results in significantly higher sequence
coverage and confidence in protein identification than traditional 'Data
Dependent Acquisition' (DDA) MS/MS methods.
Agilent Technologies introduces new mass
spectrometer product line
Agilent Technologies has introduced an entire portfolio of
chromatography-based mass spectrometry (LC/MS) systems that is expected to
nearly double its LC/MS market share by 2008. The new Agilent 6000 Series LC/MS
portfolio is expected to set a new standard in price-performance, reliability
and ease-of-use that will transform productivity in the laboratory.
The Agilent 6000 Series will include five classes of
instruments, including the company's first triple quadrupole (triple quad) and
quadrupole time-of-flight (Q-TOF) mass spectrometers. With these additional
instruments, Agilent now will be able to address nearly 70 percent of the
estimated $1.3 billion LC/MS instrument market - more than double its current
market opportunity. The 6000 Series also includes improved versions of Agilent's
single quadrupole, ion trap and time-of-flight (TOF) mass spectrometers.
"We are applying the same strategy to succeed in the
LC/MS market that we used to become a leader in gas-chromatography/mass
spectrometry," said Chris van Ingen, president of Agilent's life science
and chemical analysis business. "We are introducing products that match or
exceed the highest performance in the industry, while also providing a level of
reliability and ease-of-use that will make customers' work easier, increase
their productivity and expand the breadth of applications for which they can use
each product."
Each of the new LC/MS instruments includes the following three features that
are unique to Agilent: its proprietary autotune technology which automatically
calibrates the instrument with the click of the mouse, optimizing for
sensitivity and mass accuracy; compatibility with Agilent's multimode source
and HPLC-Chip technology; and Integrated LC and MS software for instrument
control and data analysis.
Pall, Biotrace ink global marketing pact
Pall Corporation has entered into an agreement with Biotrace
International Plc giving Pall exclusive global marketing and distribution rights
to the range of Ascotec environmental air monitoring products for the
pharmaceutical industry. As part of the worldwide agreement, the two companies
will also work together on the development of additional innovative products for
the rapid detection of contamination. Microbiological monitoring of
manufacturing processes is critical to ensuring compliance with regulatory
requirements and product safety.
The Ascotec products are used to monitor the quality of the
air and compressed gases in the production environment. They are used wherever
clean rooms are required for manufacturing of pharmaceuticals, personal
healthcare products and cosmetics and in other clinical environments such as
hospitals to reliably capture bacteria in the environment for subsequent
monitoring. The agreement will provide industry the ability to access the
Ascotec air monitoring technologies to better enable them to achieve the goals
of the US FDA Process Analytical Technology (PAT) initiative. The PAT initiative
encourages manufacturers to adopt new analytical technologies to better control
manufacturing processes and provide greater assurances of product safety.
"The addition of the Ascotec air sampler to our rapid
microbiology platform, including the Pallchek monitor, gives customers around
the globe access to a proven technology that meets the most stringent clean room
standards. It is an ideal complement to our capabilities in process and
environmental monitoring technology and aligns with our business strategy to be
a total solutions provider for the biotech and pharmaceutical industry,"
said Ken Frank, president, Pall Biopharmaceuticals.
Ian Johnson, CEO of Biotrace, said, "The combination of Pall's
filtration technologies and know-how with our technologies and expertise in
rapid microbiology will create the next generation of fast testing solutions
reducing the 'time to result' and improving production efficiency."
Aseptic Technologies, Sartorius sign distribution
agreement
Aseptic Technologies SA, an affiliate of GSK Biologicals based in Les Isnes,
Belgium, and Sartorius AG based in Goettingen, Germany, announced the formal
launch of a business partnership and exclusive global distribution agreement for
a novel aseptic liquid transfer system developed by Aseptic Technologies. The
system comprising an optimized transfer port and disposable presterilized
connection device facilitates risk-free transfer of sterile liquid to and from a
contained area, with a minimal amount of ergonomic manipulation. The connection
system has been successfully developed and validated to allow transfer of
sterile liquid through any type of walls that separate two areas with different
levels of containment. The various applications include transfer from an
external area to a cleanroom, transfer from within a cleanroom to isolators used
as barriers or transfer inside incubators. The principle is based on the La
Calhène concept of the transfer port and uses a gamma-sterilized connection
device consisting of a plastic hose barb connector inside a removable protective
sheath. The opening of the port inside the contained area releases only the
sterile part of the device, allowing easy and safe connection of tubing and
transfer of liquid. The device can be installed on various container types such
as gamma-sterilized containers (eg, collapsible bags) or steam-sterilized con
tainers (eg, stainless steel and glass vessels). Under the terms of this
agreement, Sartorius will hold the exclusive rights to market and distribute
Aseptic Technologies' sterile liquid transfer system on a global basis. The
companies will also commit resources to jointly develop the products to meet
ongoing market expectations.
Page(s) 1 |